Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 FDA approvals usher in the post-interferon era in HCV.

× No keyword cloud information.

3 in total

Review 1. Direct-acting antiviral agents for hepatitis C virus infection.

Authors: Jennifer J Kiser; Charles Flexner
Journal: Annu Rev Pharmacol Toxicol Date: 2012-11-05 Impact factor: 13.820

2. Application of the phosphoramidate ProTide approach to 4'-azidouridine confers sub-micromolar potency versus hepatitis C virus on an inactive nucleoside.

Authors: Plinio Perrone; Giovanna M Luoni; Mary Rose Kelleher; Felice Daverio; Annette Angell; Sinead Mulready; Costantino Congiatu; Sonal Rajyaguru; Joseph A Martin; Vincent Levêque; Sophie Le Pogam; Isabel Najera; Klaus Klumpp; David B Smith; Christopher McGuigan
Journal: J Med Chem Date: 2007-03-17 Impact factor: 7.446

3. Hepatitis C: move over interferon.

Authors: Ken Garber
Journal: Nat Biotechnol Date: 2011-11-08 Impact factor: 54.908

3 in total

8 in total

1. Sovaldi makes blockbuster history, ignites drug pricing unrest.

Authors: Melanie Senior
Journal: Nat Biotechnol Date: 2014-06 Impact factor: 54.908

2. Measuring fate and rate of single-molecule competition of amplification and restriction digestion, and its use for rapid genotyping tested with hepatitis C viral RNA.

Authors: Bing Sun; Jesus Rodriguez-Manzano; David A Selck; Eugenia Khorosheva; Mikhail A Karymov; Rustem F Ismagilov
Journal: Angew Chem Int Ed Engl Date: 2014-06-02 Impact factor: 15.336

3. Industry chases pan-genotypic and shorter HCV treatments.

Authors: Anna Azvolinsky
Journal: Nat Biotechnol Date: 2015-06 Impact factor: 54.908

4. A Cost-Utility Analysis of Different Antiviral Medicine Regimens in Patients With Chronic Hepatitis C Virus Genotype 1 Infection.

Authors: Seyed Moayed Alavian; Shekoufeh Nikfar; Abbas Kebriaeezadeh; Farhad Lotfi; Ehsan Sanati; Mohsen Rezaei Hemami; Khosro Keshavarz
Journal: Iran Red Crescent Med J Date: 2016-10-02 Impact factor: 0.611

5. Multi-disciplinary patient-centered model for the expedited provision of costly therapies in community settings: the case of new medication for hepatitis C.

Authors: Nitzan Avisar; Yael Heller; Clara Weil; Aviva Ben-Baruch; Shani Potesman-Yona; Ran Oren; Gabriel Chodick; Varda Shalev; Nachman Ash
Journal: Isr J Health Policy Res Date: 2017-09-28

6. Efficient Synthesis and Docking Studies of Novel Benzothiazole-Based Pyrimidinesulfonamide Scaffolds as New Antiviral Agents and Hsp90α Inhibitors.

Authors: Rasha A Azzam; Rokia R Osman; Galal H Elgemeie
Journal: ACS Omega Date: 2020-01-09

7. Trends in clinical development timeframes for antiviral drugs launched in the UK, 1981-2014: a retrospective observational study.

Authors: Derek J Ward; Edward Hammond; Luan Linden-Phillips; Andrew J Stevens
Journal: BMJ Open Date: 2015-11-16 Impact factor: 2.692

Review 8. Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism.

Authors: Nikolaos Tsesmetzis; Cynthia B J Paulin; Sean G Rudd; Nikolas Herold
Journal: Cancers (Basel) Date: 2018-07-23 Impact factor: 6.639

8 in total